Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

27.79 -0.29 (-1.03%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome

April 13, 2023

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals - An Emerging Leader In ALS ↗

April 12, 2023

Amylyx has sold off from its earnings report on March 13th. What has been driving this move and what does it mean for the long term prospects of Amylyx?

Via Talk Markets

Amylyx Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 11, 2023

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Analyst Ratings for Amylyx Pharma ↗

March 31, 2023

Via Benzinga

Expert Ratings for Amylyx Pharma ↗

March 31, 2023

Via Benzinga

Looking Into Amylyx Pharmaceuticals's Return On Capital Employed ↗

March 15, 2023

Via Benzinga

Analyst Expectations for Amylyx Pharma's Future ↗

March 14, 2023

Via Benzinga

Why Amylyx Pharmaceuticals Stock Is Bolting Higher Today ↗

March 14, 2023

The biopharma's new ALS drug is exceeding projections on the sales front.

Via The Motley Fool

7 Biotech Stocks to Buy for 100% Returns ↗

April 09, 2023

If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023 ↗

March 31, 2023

Via Benzinga

Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review ↗

March 17, 2023

A market rally is underway, but bank stocks kept tumbling.

Via Investor's Business Daily

Amylyx, A Top 5% Biotech Stock, Just Scored A Huge Win In ALS Treatment ↗

March 14, 2023

Analysts saw just $4.7 million in sales of Relyvrio. Amylyx blew that out of the water.

Via Investor's Business Daily

Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 14, 2023

Gainers Ainos, Inc. (NASDAQ: AIMD) shares jumped 69.3% to $1.27 after the company announced it signed a Memorandum of Understanding with Merdury Biopharmaceutical to jointly explore and develop a...

Via Benzinga

First Republic Bank, PacWest Bancorp, Western Alliance Bancorporation And Other Big Stocks Moving Higher On Tuesday ↗

March 14, 2023

U.S. stocks traded higher, with the Nasdaq Composite gaining more than 200 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 14, 2023

Via Benzinga

Jabil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

March 14, 2023

Raymond James raised the price target for Jabil Inc. (NYSE: JBL) from $84 to $100. Raymond James analyst Melissa Fairbanks maintained a Strong Buy rating. Jabil shares fell 0.7% to close at $81.35 on...

Via Benzinga

Why PacWest Bancorp Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket ↗

March 14, 2023

Gainers PacWest Bancorp (NASDAQ: PACW) rose 29.9% to $12.66 in pre-market trading after multiple insider buys by Officers, Directors reported late Monday.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

March 14, 2023

We're starting off the day with an overview of the biggest pre-market stock movers investors need to keep an eye on for Tuesday!

Via InvestorPlace

12 Health Care Stocks Moving In Monday's After-Market Session ↗

March 13, 2023

Via Benzinga

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

March 13, 2023

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

March 08, 2023

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023

March 07, 2023

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Mixed Signals On Valentine's Day: How Stocks Are Reacting To January Inflation Data ↗

February 14, 2023

Inflation cooled slightly in January, but saw increases in some areas due to the impact of surging food, energy and shelter prices on consumers, the U.S Labor Department said Tuesday.

Via Benzinga

Amylyx Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference

February 07, 2023

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Announces Completion of Enrollment in Global Phase 3 PHOENIX Trial of AMX0035 in ALS

February 02, 2023

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗

January 05, 2023

Via Benzinga

100 Best Stocks Of 2022: Fossil Fuel Ignites, Solar Shines, Meds Make Miracles ↗

December 30, 2022

Energy and medical plays top the 100 Best Stocks of 2022. It makes sense, given world events that shifted the first-quarter playing field.

Via Investor's Business Daily

Amylyx Pharmaceuticals to Participate in the Evercore ISI 5th Annual HealthCONx Conference

November 22, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm ↗

November 16, 2022

Neurodegenerative disorders could mean big bucks for some biotechs.

Via Investor's Business Daily

Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results

November 10, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.